Hegde, P. S. & Chen, D. S. Prime 10 challenges in most cancers immunotherapy. Immunity 52, 17–35 (2020).
Mo, H. et al. Security, anti-tumour exercise, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in superior stable tumours: a dose-escalation, section 1 examine. Br. J. Most cancers 119, 538–545 (2018).
Carrick, S. et al. Single agent versus mixture chemotherapy for metastatic breast most cancers. Cochrane Database Syst. Rev. 2009, CD003372 (2009).
Moy, B. et al. Chemotherapy and focused remedy for sufferers with human epidermal development issue receptor 2-negative metastatic breast most cancers that’s both endocrine-pretreated or hormone receptor-negative: ASCO guideline replace. J. Clin. Oncol. 39, 3938–3958 (2021).
Ozaki, Y. et al. Security and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast most cancers: main outcomes and biomarker information from a section 2 trial (WJOG9917B). Eur. J. Most cancers 171, 193–202 (2022).
Cortes, J. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for beforehand untreated domestically recurrent inoperable or metastatic triple-negative breast most cancers (KEYNOTE-355): a randomised, placebo-controlled, double-blind, section 3 medical trial. Lancet 396, 1817–1828 (2020).
Jiang, Z. et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast most cancers: a randomized section 3 trial. Nat. Med. 30, 249–256 (2024).
Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets related to response to PD-L1 blockade in triple-negative breast most cancers. Most cancers Cell 39, 1578–1593 (2021).
Miles, D. W. et al. First-line bevacizumab together with chemotherapy for HER2-negative metastatic breast most cancers: pooled and subgroup analyses of knowledge from 2447 sufferers. Ann. Oncol. 24, 2773–2780 (2013).
Pasquier, E., Kavallaris, M. & André, N. Metronomic chemotherapy: new rationale for brand new instructions. Nat. Rev. Clin. Oncol. 7, 455–465 (2010).
André, N., Carré, M. & Pasquier, E. Metronomics: in direction of customized chemotherapy? Nat. Rev. Clin. Oncol. 11, 413–431 (2014).
Orecchioni, S. et al. Vinorelbine, cyclophosphamide and 5-FU results on the circulating and intratumoural panorama of immune cells enhance anti-PD-L1 efficacy in preclinical fashions of breast most cancers and lymphoma. Br. J. Most cancers 118, 1329–1336 (2018).
Munzone, E. et al. Efficacy of metronomic oral vinorelbine, cyclophosphamide, and capecitabine vs weekly intravenous paclitaxel in sufferers with estrogen receptor-positive, ERBB2-negative metastatic breast most cancers: closing outcomes from the section 2 METEORA-II randomized medical trial. JAMA Oncol. 9, 1267–1272 (2023).
Gubin, M. M. et al. Excessive-dimensional evaluation delineates myeloid and lymphoid compartment reworking throughout profitable immune-checkpoint most cancers remedy. Cell 175, 1014–1030 (2018).
Onkar, S. S. et al. The good immune escape: understanding the divergent immune response in breast most cancers subtypes. Most cancers Discov. 13, 23–40 (2023).
Shaked, Y. The professional-tumorigenic host response to most cancers therapies. Nat. Rev. Most cancers 19, 667–685 (2019).
Ho, W. J. et al. Built-in immunological evaluation of a profitable conversion of domestically superior hepatocellular carcinoma to resectability with neoadjuvant remedy. J. Immunother. Most cancers 8, e000932 (2020).
Hiam-Galvez, Okay. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in most cancers. Nat. Rev. Most cancers 21, 345–359 (2021).
Monjazeb, A. M. et al. A randomized trial of mixed PD-L1 and CTLA-4 inhibition with focused low-dose or hypofractionated radiation for sufferers with metastatic colorectal most cancers. Clin. Most cancers Res. 27, 2470–2480 (2021).
Simonds, E. F. et al. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J. Immunother. Most cancers 9, e002181 (2021).
Lheureux, S. et al. Translational randomized section II trial of cabozantinib together with nivolumab in superior, recurrent, or metastatic endometrial most cancers. J. Immunother. Most cancers 10, e004233 (2022).
Rochigneux, P. et al. Mass cytometry reveals classical monocytes, NK cells, and ICOS+ CD4+ T cells related to pembrolizumab efficacy in sufferers with lung most cancers. Clin. Most cancers Res. 28, 5136–5148 (2022).
Chapman, A. et al. CD11b+CD28−CD4+ human T cells: activation necessities and affiliation with HLA-DR alleles. J. Immunol. 157, 4771–4780 (1996).
Markovic-Plese, S., Cortese, I., Wandinger, Okay. P., McFarland, H. F. & Martin, R. CD4+CD28− costimulation-independent T cells in a number of sclerosis. J. Clin. Investig. 108, 1185–1194 (2001).
Alegre, M.-L., Frauwirth, Okay. A. & Thompson, C. B. T-cell regulation by CD28 and CTLA-4. Nat. Rev. Immunol. 1, 220–228 (2001).
Wendel, M., Galani, I. E., Suri-Payer, E. & Cerwenka, A. Pure killer cell accumulation in tumors depends on IFN-γ and CXCR3 ligands. Most cancers Res. 68, 8437–8445 (2008).
Wu, M., Fang, H. & Hwang, S. T. Innovative: CCR4 mediates antigen-primed T cell binding to activated dendritic cells. J. Immunol. 167, 4791–4795 (2001).
Bromley, S. Okay., Thomas, S. Y. & Luster, A. D. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 6, 895–901 (2005).
Gregory, J. L. et al. Macrophage migration inhibitory issue induces macrophage recruitment by way of CC chemokine ligand 2. J. Immunol. 177, 8072–8079 (2006).
Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to manage T cell demise and is a goal for most cancers immunotherapy. Nat. Commun. 12, 832 (2021).
Sugimoto, M. A., Vago, J. P., Teixeira, M. M. & Sousa, L. P. Annexin A1 and the decision of irritation: modulation of neutrophil recruitment, apoptosis, and clearance. J. Immunol. Res. 2016, 8239258 (2016).
Socinski, M. A. et al. Atezolizumab for first-line therapy of metastatic nonsquamous NSCLC. N. Engl. J. Med. 378, 2288–2301 (2018).
Shitara, Okay. et al. Efficacy and security of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for sufferers with first-line, superior gastric most cancers: the KEYNOTE-062 section 3 randomized medical trial. JAMA Oncol. 6, 1571–1580 (2020).
Tune, Y. et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind section 3 trial. Nat. Med. 29, 473–482 (2023).
Colombo, N. et al. Pembrolizumab for persistent, recurrent, or metastatic cervical most cancers. N. Engl. J. Med. 385, 1856–1867 (2021).
Zhang, Z. et al. An actual-world examine of immune checkpoint inhibitors in superior triple-negative breast most cancers. Most cancers Innov. 2, 172–180 (2023).
Miles, D. et al. Main outcomes from IMpassion131, a double-blind, placebo-controlled, randomised section III trial of first-line paclitaxel with or with out atezolizumab for unresectable domestically superior/metastatic triple-negative breast most cancers. Ann. Oncol. 32, 994–1004 (2021).
Schmid, P. et al. Atezolizumab plus nab-paclitaxel as first-line therapy for unresectable, domestically superior or metastatic triple-negative breast most cancers (IMpassion130): up to date efficacy outcomes from a randomised, double-blind, placebo-controlled, section 3 trial. Lancet Oncol. 21, 44–59 (2020).
Schmid, P. et al. Atezolizumab and nab-paclitaxel in superior triple-negative breast most cancers. N. Engl. J. Med. 379, 2108–2121 (2018).
Vicier, C. et al. MOVIE: a section I, open-label, multicenter examine to judge the security and tolerability of metronomic vinorelbine mixed with durvalumab plus tremelimumab in sufferers with superior stable tumors. ESMO Open 7, 100646 (2022).
Patil, V. M. et al. Low-dose immunotherapy in head and neck most cancers: a randomized examine. J. Clin. Oncol. 41, 222–232 (2023).
Zsiros, E. et al. Efficacy and security of pembrolizumab together with bevacizumab and oral metronomic cyclophosphamide within the therapy of recurrent ovarian most cancers: a section 2 nonrandomized medical trial. JAMA Oncol. 7, 78–85 (2021).
Vergnenegre, A. et al. Security and efficacy of second-line metronomic oral vinorelbine-atezolizumab mixture in stage IV non-small-cell lung most cancers: an open-label section II trial (VinMetAtezo). Lung Most cancers 178, 191–197 (2023).
Cortes, J. et al. Pembrolizumab plus chemotherapy in superior triple-negative breast most cancers. N. Engl. J. Med. 387, 217–226 (2022).
André, N. et al. Mathematical mannequin of most cancers development controled by metronomic chemotherapies. ESAIM Proc. 41, 77–94 (2013).
Huang, Y. et al. Vascular normalizing doses of antiangiogenic therapy reprogram the immunosuppressive tumor microenvironment and improve immunotherapy. Proc. Natl Acad. Sci. USA 109, 17561–17566 (2012).
Curigliano, G. et al. Antiangiogenic remedy in recurrent breast most cancers with lymphangitic unfold to the chest wall: a randomized section II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. Breast 24, 263–271 (2015).
Xu, B. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative superior breast most cancers: a randomized, section 3 trial. Nat. Med. 27, 1904–1909 (2021).
Muss, H. B. et al. Toxicity of older and youthful sufferers handled with adjuvant chemotherapy for node-positive breast most cancers: the Most cancers and Leukemia Group B Expertise. J. Clin. Oncol. 25, 3699–3704 (2007).
Montagna, E. et al. Security and efficacy examine of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast most cancers: a section II trial. Most cancers Lett. 400, 276–281 (2017).
Butler, C. C. et al. Molnupiravir plus standard care versus standard care alone as early therapy for adults with COVID-19 at elevated threat of adversarial outcomes (PANORAMIC): an open-label, platform-adaptive randomised managed trial. Lancet 401, 281–293 (2023).
Reis, G. et al. Impact of early therapy with ivermectin amongst sufferers with Covid-19. N. Engl. J. Med. 386, 1721–1731 (2022).
Puduvalli, V. Okay. et al. A Bayesian adaptive randomized section II multicenter trial of bevacizumab with or with out vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 22, 1505–1515 (2020).
Voorwerk, L. et al. Immune induction methods in metastatic triple-negative breast most cancers to boost the sensitivity to PD-1 blockade: the TONIC trial. Nat. Med. 25, 920–928 (2019).
Debien, V. et al. Immunotherapy in breast most cancers: an summary of present methods and views. npj Breast Most cancers 9, 7 (2023).
Kirchhammer, N., Trefny, M. P., Auf der Maur, P., Läubli, H. & Zippelius, A. Mixture most cancers immunotherapies: rising therapy methods tailored to the tumor microenvironment. Sci. Transl. Med. 14, eabo3605 (2022).
Galon, J. & Bruni, D. Approaches to deal with immune sizzling, altered and chilly tumours with mixture immunotherapies. Nat. Rev. Drug Discov. 18, 197–218 (2019).
Rahim, M. Okay. et al. Dynamic CD8+ T cell responses to most cancers immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186, 1127–1143 (2023).
Peng, H. et al. Neoadjuvant FOLFIRINOX remedy is related to elevated effector T cells and diminished suppressor cells in sufferers with pancreatic most cancers. Clin. Most cancers Res. 27, 6761–6771 (2021).
Chong, E. A. et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell remedy. Blood 139, 1026–1038 (2022).
Berry, D. A. Adaptive medical trials in oncology. Nat. Rev. Clin. Oncol. 9, 199–207 (2011).
Berry, D. A. Bayesian medical trials. Nat. Rev. Drug Discov. 5, 27–36 (2006).
Yu, S. et al. Distinct immune signatures discriminate between asymptomatic and presymptomatic SARS-CoV-2pos topics. Cell Res. 31, 1148–1162 (2021).
Zhang, Q. et al. Mass cytometry-based peripheral blood evaluation as a novel device for early detection of stable tumours: a multicentre examine. Intestine 72, 996–1006 (2023).
Zunder, E. R. et al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme and single-cell deconvolution algorithm. Nat. Protoc. 10, 316–333 (2015).
Finck, R. et al. Normalization of mass cytometry information with bead requirements. Cytometry A 83, 483–494 (2013).
Samusik, N., Good, Z., Spitzer, M. H., Davis, Okay. L. & Nolan, G. P. Automated mapping of phenotype house with single-cell information. Nat. Strategies 13, 493–496 (2016).
Berry, S. M., Carlin, B. P., Lee, J. J. & Muller, P. Bayesian Adaptive Strategies for Scientific Trials (CRC Press, 2010).
Harari, O. et al. Using Bayesian predictive energy in medical trial design. Pharm. Stat. https://doi.org/10.1002/pst.2073 (2020).
